Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HXHongyun Xing

Discussion

Loading...

Member takes

Overview

Clinical studies demonstrate improved complete response with zanubrutinib and chemotherapy in relapsed DLBCL, suggesting better outcomes for patients.

Key Points

  • This research aims to evaluate the efficacy and safety of zanubrutinib combined with chemotherapy in relapsed/refractory DLBCL patients.
  • Analyzed clinical data of 24 patients with r/r DLBCL from June 2023 to July 2025.
  • Patients received various chemotherapy regimens combined with zanubrutinib, including R-CHOP and R-GemOx.
  • Efficacy was evaluated using PET/CT imaging.
  • Overall objective response rate (ORR) was 75%, with a complete response (CR) rate of 33.3%.
  • Patients treated with R-CHOP achieved a 100% ORR, while R-GemOx had a 75% ORR.
  • Grade ≥3 adverse events included neutropenia (58.3%) and pulmonary infection (45.8%).

Cite This Study

Hongyun Xing (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2a3https://doi.org/10.1182/blood-2025-7218
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL2026
  2. 2Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025
  3. 3A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma2026
  4. 4Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma2025
  5. 5Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma2026